Profile: Acceleron Pharma Inc (XLRN.O)
26 May 2017
Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas.
Luspatercept is designed to promote red blood cell production through a mechanism, and it is developing luspatercept with Celgene Corporation (Celgene) to treat anemia and associated complications in myelodysplastic syndromes (MDS), beta-thalassemia, and myelofibrosis. Celgene is conducting a Phase III clinical trial with luspatercept in patients with very low, low and intermediate risk MDS per the Revised International Prognostic Scoring System, the MEDALIST trial. In addition to the Phase III clinical trial, it is conducting two Phase II clinical trials of luspatercept in patients with MDS. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. Sotatercept is being studied through investigator-initiated clinical trials in multiple myeloma, Diamond-Blackfan anemia and myelofibrosis.
The Company is developing dalantercept primarily for use in combination with vascular endothelial growth factor (VEGF) pathway inhibitors to produce outcomes for cancer patients. It is evaluating dalantercept in combination with axitinib, a tyrosine kinase inhibitor of the VEGF pathway, for the treatment of renal cell carcinoma in the DART trial, a two part Phase II clinical trial. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles. The Company has completed a Phase I clinical trial with ACE-083 in healthy volunteers. It has completed the Phase I clinical trial and also initiated a Phase II clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy (FSHD).
Acceleron Pharma Inc
128 Sidney St
CAMBRIDGE MA 02139-4239
Company Web Links
- BRIEF-Acceleron Pharma qtrly loss per share $0.66
- BRIEF-Acceleron announces management change
- BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2
- BRIEF-Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease
- BRIEF-Acceleron outlines corporate goals and priorities for 2017